Pick Bodies is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Pick bodies are spherical, intraneuronal inclusions composed of aggregated tau protein that are the neuropathological hallmark of Pick's disease (PiD), a subtype of frontotemporal lobar degeneration (FTLD).[1] These distinctive inclusions were first described by Alois Alzheimer in 1911 and remain a defining diagnostic feature of Pick's disease, differentiating it from other tauopathies such as Alzheimer's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD).[2]
Pick bodies are composed predominantly of three-repeat (3R) tau isoforms, distinguishing them from other tauopathies that feature four-repeat (4R) tau or mixed 3R/4R tau aggregates. This unique biochemical signature makes Pick bodies a key diagnostic feature in neuropathological evaluation and has made Pick's disease a critical model for understanding tau protein aggregation in neurodegeneration.[3]
Pick bodies are primarily composed of the three-repeat (3R) isoform of the tau protein, in contrast to other tauopathies:[4]
The selective accumulation of 3R tau in Pick bodies results from alternative splicing of the MAPT (microtubule-associated protein tau) gene, specifically exon 10 splicing that controls the inclusion of the second microtubule-binding repeat.[5]
Pick body tau exhibits several post-translational modifications:[6]
Pick bodies appear as round, spherical inclusions within the cytoplasm of neurons:[7]
Ultrastructurally, Pick bodies consist of:[8]
Pick bodies preferentially accumulate in specific brain regions:[9]
The distribution correlates with the characteristic frontotemporal atrophy seen in Pick's disease and explains the early behavioral and language symptoms.[10]
The formation of Pick bodies involves several interconnected mechanisms:[11]
Mutations in the MAPT gene associated with Pick's disease:[12]
Pick body formation is closely linked to neuronal dysfunction:[13]
Pick bodies provide definitive neuropathological diagnosis of Pick's disease:[14]
The distribution of Pick bodies correlates with clinical presentation:[15]
Transgenic models reproducing Pick body-like pathology:[16]
In vitro systems for studying Pick body formation:[17]
Therapeutic strategies under investigation:[18]
Specific challenges in targeting Pick body tau:[19]
| Tauopathy | Primary Isoform | Key Inclusions | Clinical Features |
|---|---|---|---|
| Pick's disease | 3R | Pick bodies | bvFTD, semantic aphasia |
| Alzheimer's disease | 3R + 4R | Neurofibrillary tangles | Memory impairment |
| PSP | 4R | Tufted astrocytes, PSP tangles | Vertical gaze palsy |
| CBD | 4R | Astrocytic plaques, CBD tangles | Apraxia, alien limb |
The study of Pick Bodies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;120(1):67-81. PMID:20563774
Alzheimer A. About peculiar severe disease processes of the cerebral cortex. 1911. J Neural Transm (Vienna). 2017;124(Suppl 1):3-7. PMID:28119881
Irwin DJ, Brettschweiler J, Cairns NJ, et al. Frontotemporal lobar degeneration: phenotypic, pathological and biochemical heterogeneity. Nat Rev Neurol. 2016;12(10):598. PMID:27686761
Buee L, Delacourte A. Tauopathy: a new concept in neurodegeneration. Med Sci (Paris). 2019;35(10):751-760. PMID:31693862
Goedert M, Spillantini MG. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609-622. PMID:23670185
Wray S. Tau protein: the quest for diagnostic and therapeutic targets. J Mol Neurosci. 2011;45(3):449-455. PMID:21720752
Armstrong RA, Lantos PL, Cairns NJ. Spatial distribution of Pick bodies, Pick cells and the disease stage in Pick's disease. Neuropathology. 2000;20(3):165-173. PMID:11037037
Arima K. Ultrastructural characteristics of Pick bodies and Pick cell process in the dentate granule cell in Pick's disease. Brain Res. 2000;877(2):311-322. PMID:10986348
Kril JJ, Macdonald V, Patel S, Png F, Halliday GM. Pick bodies have a specific topographical distribution in mild Pick's disease. Acta Neuropathol. 2005;109(6):643-653. PMID:15812575
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477. PMID:21810890
Gotz J, Xia D, Leinenga G, Lisowski Y, Ittner LM. What renders tau toxic. Front Neurol. 2013;4:72. PMID:23781207
Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with inherited dementia. Nature. 1998;393(6686):702-705. PMID:9674264
Tai HC, Serrano-Pozo A, Hashimoto T, et al. The synaptic accumulation of hyperphosphoryzed tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012;181(4):1426-1435. PMID:22867711
McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001;58(11):1803-1809. PMID:11708987
Snowden JS, Neary D, Mann DM. Frontotemporal dementia. Br J Psychiatry. 2002;180:140-143. PMID:11823325
Ramsden M, Kotilinek L, Forster C, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci. 2005;25(46):10637-10647. PMID:16291936
Usenovic M, Kaine J, Alvarez D. Tau biology and tau-targeted therapies in neurodegenerative diseases. CNS Drugs. 2019;33(6):539-547. PMID:31123932
Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener. 2009;4:13. PMID:19284597
Boccardi V, Mecocci P. Tau phosphorylation and aggregation in Alzheimer's disease: possible involvement of oxidative stress. J Alzheimer's Dis. 2012;31(3):421-428. PMID:22555375
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 19 references |
| Replication | 0% |
| Effect Sizes | 50% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 51%